US FDA’s Cosmetics Director Katz Cites Fragrance Allergens, Talc-Containing Products Among Priorities
Executive Summary
Linda Katz, director of the US FDA’s Office of Cosmetics and Colors, offered insight into priority cosmetics issues at the Independent Beauty Association’s virtual FDA Cosmetic Regulations Workshop.
You may also be interested in...
ICCR’s Growing Membership Ensures Diverse Cosmetics Regulatory Perspectives – PCPC
South Korea’s Ministry of Food and Drug Safety and Taiwan’s Food and Drug Administration will transition from ICCR observers to full members, joining regulatory authorities from the US, Europe, Japan, Canada and Brazil. PCPC’s Francine Lamoriello, EVP of global affairs, discusses.
European Lab Network Finds 80% Of Cosmetics Regulatory-Compliant, 59% Of Perfumes
A market surveillance study by the European Network of Official Cosmetics Control Laboratories found that roughly 8% of cosmetic product samples were not properly labeled to alert consumers to the presence of allergenic fragrance compounds. The investigators also report preservative problems and microbiological contamination, among other issues.
US FDA’s Stance On CBD In Cosmetics Hasn’t Changed, And Neither Have Marketing Challenges
The FDA continues working to close cannabidiol data gaps while maintaining that CBD-containing cosmetics cannot be adulterated, misbranded or marketed as affecting body structure/function or treating or preventing disease, including skin ailments. Cosmetics office head Linda Katz revisited the issue during the Independent Beauty Association’s annual FDA Cosmetics Regulations Workshop.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: